BullishAgent BullishAgent SEC Filings Earnings Calendar Analyst Ratings IPOs Insiders Institutional Funds Screener
Sign in Register

BAX

Baxter International Inc. NYSE
Healthcare ·Medical - Instruments & Supplies ·US · baxter.com
$17.21
Mkt Cap $8.8B
52w Low $15.73 8.7% of range 52w High $32.68
50d MA $18.10 200d MA $20.84
P/E (TTM) -9.8x
EV/EBITDA 23.3x
P/B 1.4x
Debt/Equity 1.6x
ROE -15.6%
P/FCF 30.4x
RSI (14)
ATR (14)
Beta 0.62
50d MA $18.10
200d MA $20.84
Avg Volume 9.5M
About
Baxter International Inc., through its subsidiaries, develops and provides a portfolio of healthcare products worldwide. The company offers peritoneal dialysis and hemodialysis, and additional dialysis therapies and services; intravenous therapies, infusion pumps, administration sets, and drug reconstitution devices; remixed and oncology drug platforms, inhaled anesthesia and critical care product…
Recent Earnings
Date Time Est Rptd Surp Base Gap% D1% D2% D3% D4% D5% 1M% Guide ▲★
Apr 30, 2026 BMO 0.31 0.36 +16.1% 16.90 +4.9% +4.0% +1.8%
Feb 12, 2026 BMO 0.53 0.44 -17.0% 22.28 -12.4% -16.0% -11.2% -6.9% -1.8% -4.2% -23.3%
Oct 30, 2025 BMO 0.60 0.69 +15.0% 22.42 -15.5% -14.5% -17.6% -18.8% -20.0% -19.9% -14.9%
Jul 31, 2025 BMO 0.60 0.59 -1.7% 28.05 -15.3% -22.4% -21.7% -20.0% -18.6% -19.8% -13.8%
May 1, 2025 BMO 0.48 0.55 +13.8% 31.17 +3.1% -1.6% -1.5% -2.4% -4.0% -1.4% -5.2%
Feb 20, 2025 BMO 0.53 0.58 +9.8% 30.82 +8.0% +8.5% +9.7% +13.8% +16.6% +14.4% +9.0%
Nov 8, 2024 BMO 0.78 0.80 +2.6% 36.04 -1.6% -3.9% -5.0% -6.1% -9.5% -12.0% -11.6%
Aug 6, 2024 BMO 0.66 0.68 +2.7% 34.64 +1.0% +6.6% +5.6% +8.0% +7.2% +6.6% +12.1%
May 2, 2024 BMO 0.61 0.65 +7.1% 40.34 -3.1% -8.5% -8.6% -9.5% -10.5% -11.4% -15.5%
Feb 8, 2024 BMO 0.86 0.88 +2.3% 39.38 -1.0% +2.7% +0.4% +2.4% +0.6% +0.7% +10.4%
Recent Analyst Ratings
Date Firm Action Grade Target Base Open Gap% D1% D2% D3% D4% D5%
Apr 6 Evercore ISI Maintains Outperform → Outperform $16.68 $16.66 -0.1% -0.2% -0.4% +3.4% +3.7% +2.8%
Mar 11 Citigroup Maintains Neutral → Neutral $17.46 $17.51 +0.3% +3.4% +3.2% -0.3% -2.2% +0.9%
Feb 17 Goldman Sachs Maintains Neutral → Neutral $19.79 $20.09 +1.5% +4.8% +10.5% +7.8% +9.0% +7.4%
Feb 13 Barclays Maintains Overweight → Overweight $18.71 $18.67 -0.2% +5.8% +10.8% +16.9% +14.1% +15.3%
Jan 9 Barclays Maintains Overweight → Overweight $20.69 $20.90 +1.0% +1.8% -2.6% -5.0% -4.1% -1.5%
Dec 2 Morgan Stanley Maintains Underweight → Underweight $19.08 $18.99 -0.5% -1.3% -1.0% -3.1% -2.8% -4.8%
Oct 31 Citigroup Maintains Neutral → Neutral $19.16 $18.81 -1.8% -3.6% -5.0% -6.4% -6.3% -6.2%
Oct 31 Goldman Sachs Maintains Neutral → Neutral $19.16 $18.81 -1.8% -3.6% -5.0% -6.4% -6.3% -6.2%
Oct 31 Argus Downgrade Buy → Hold $19.16 $18.81 -1.8% -3.6% -5.0% -6.4% -6.3% -6.2%
Oct 31 UBS Maintains Neutral → Neutral $19.16 $18.81 -1.8% -3.6% -5.0% -6.4% -6.3% -6.2%
Recent Filings
8-K · 5.02 !!! Very High
Unknown — 8-K 5.02: Executive Change
Vafa Jamali's appointment as director signals potential strategic shifts in governance and decision-making, warranting investor attention to board composition changes affecting corporate direction and oversight quality.
Apr 6
8-K · 5.02 !!! Very High
Unknown — 8-K 5.02: Executive Change
A new executive at Baxter or Inogen with a $525,000 base salary and 70% bonus potential signals leadership continuity, but investors should monitor whether this hire strengthens operational execution or represents reactive replacement.
Mar 30
8-K · 7.01 ! Medium
Unknown — 8-K 7.01: Regulation FD Disclosure
Baxter is communicating adjusted financial metrics to shareholders, signaling management's focus on operational performance rather than reported results, which typically indicates confidence in underlying business strength despite potential accounting headwinds.
Mar 19
8-K · 7.01 ! Medium
Unknown — 8-K 7.01: Regulation FD Disclosure
Baxter International made a material announcement on March 16, 2026, requiring SEC disclosure, likely signaling executive or strategic news that could impact investor expectations and stock valuation.
Mar 16
8-K · 5.02 !!! Very High
Baxter International Inc. -- 8-K 5.02: Executive Change
Baxter International appointed Michael R. McDonnell as Executive Vice President effective February 13, 2026, signaling internal leadership development and potential changes to executive responsibilities.
Feb 12
Data updated apr 24, 2026 8:36pm · Source: massive.com